Anavar and Warfarin: The Drug Interaction That Can Cause Life-Threatening Bleeding

If you take warfarin and are considering Anavar, this article may be the most important page you read before starting your cycle. In 2004, the U.S. Food and Drug Administration issued a safety alert warning that concurrent dosing of oxandrolone and warfarin can produce unexpectedly large increases in the international normalised ratio, requiring an 80 to 85% reduction in warfarin dose to prevent serious bleeding. This is not a theoretical interaction. It was demonstrated in a controlled clinical study, it produced microscopic haematuria in 9 out of 15 subjects, and it remains one of the most dangerous drug interactions in the entire anabolic steroid pharmacopoeia. No competitor website in this niche covers the Anavar and warfarin interaction at all. At Hemi Pharma UK, we consider this omission irresponsible, because anyone on anticoagulant therapy who starts oxandrolone without understanding this interaction is at genuine risk of haemorrhagic complications.

What Did the FDA Clinical Study Find About Anavar and Warfarin Together?

The interaction was characterised in a multidose clinical study conducted by Savient Pharmaceuticals (the manufacturer of Oxandrin) and reported to the FDA in 2004. The study enrolled 15 healthy subjects who were concurrently administered oxandrolone at 5mg or 10mg twice daily alongside warfarin. The results were alarming in their magnitude.

The study found that oxandrolone increased the half-life of the more pharmacologically active S-enantiomer of warfarin from 26 hours to 48 hours, nearly doubling it. The systemic exposure (area under the curve) of S-warfarin increased from 4.55 to 12.08 ng-hr/mL, a 2.7-fold increase. The clinical consequence was that a 5.5-fold decrease in mean warfarin dose (from 6.13mg per day to 1.13mg per day) was required to maintain the target INR of 1.5. Microscopic haematuria was observed in 9 of the 15 subjects, and gingival bleeding was observed in 1 subject (FDA/Medscape, 2004).

To put these numbers in perspective: an 80 to 85% warfarin dose reduction is one of the largest drug interaction effects documented for any commonly used medication. Most drug interactions with warfarin require dose adjustments of 10 to 30%. The Anavar and warfarin interaction is in a different category entirely. It does not merely alter warfarin’s effect. It transforms a therapeutic anticoagulant dose into a potentially haemorrhagic one.

How Does Oxandrolone Potentiate Warfarin’s Anticoagulant Effect?

The mechanism involves two overlapping pharmacological pathways. Understanding both is important because it explains why the interaction is so pronounced and why simple INR monitoring may not provide adequate protection.

First, oxandrolone inhibits the hepatic metabolism of warfarin. Warfarin is metabolised primarily by cytochrome P450 enzymes in the liver, with CYP2C9 being the principal enzyme responsible for the clearance of the more active S-enantiomer. Oxandrolone, as a 17-alpha-alkylated oral steroid undergoing extensive hepatic first-pass metabolism, competes for CYP450 enzymatic capacity. This competition slows warfarin metabolism, extends its half-life (from 26 to 48 hours for S-warfarin in the clinical study), and increases systemic exposure. The result is that each warfarin dose produces a larger and longer-lasting anticoagulant effect.

Second, anabolic androgenic steroids as a class increase the sensitivity of vitamin K-dependent clotting factor synthesis to warfarin’s inhibitory effect. The prescribing information for oxandrolone notes that androgenic anabolic steroids may increase susceptibility to oral anticoagulants, with reduction of the anticoagulant dosage necessary to maintain the desired prothrombin time (Drugs.com interaction data). This pharmacodynamic enhancement operates independently of the pharmacokinetic interaction, meaning even if warfarin metabolism were unaffected, the anticoagulant response per unit of warfarin would still be increased.

The combination of slower warfarin clearance (pharmacokinetic) and enhanced anticoagulant sensitivity (pharmacodynamic) produces the extreme potentiation observed in the clinical study. It is not simply an additive effect. It is a multiplicative one.

What Are the Signs of Dangerous Bleeding From the Anavar and Warfarin Interaction?

The clinical study detected microscopic haematuria (blood in the urine, not visible to the naked eye) in 60% of subjects. This is subclinical bleeding that the subjects would not have noticed without laboratory testing. More concerning is the spectrum of overt bleeding that an unmonitored patient could experience.

Warfarin-related bleeding ranges from minor (easy bruising, prolonged bleeding from cuts, gingival bleeding, nosebleeds) to major (gastrointestinal haemorrhage, intracranial haemorrhage, retroperitoneal bleeding, haemarthrosis). When the INR rises above 4.0, the risk of major bleeding increases substantially. When it rises above 6.0, the risk of life-threatening intracranial haemorrhage becomes clinically significant. An unmonitored patient who starts Anavar while on a stable warfarin dose could see their INR rise from a therapeutic 2.0 to 3.0 range to well above 6.0 within the first week, without any outward symptoms until major bleeding occurs.

The warning signs that should trigger immediate medical evaluation include: unexplained bruising or bruises that appear without trauma; blood in the urine (pink, red, or cola-coloured); blood in the stool (black, tarry stools or visible red blood); nosebleeds that do not stop within 10 minutes; bleeding from the gums not attributable to dental work; coughing up blood; sudden severe headache, confusion, or visual changes (potential intracranial haemorrhage); unexplained abdominal pain or back pain (potential retroperitoneal bleeding). Any of these symptoms in a patient taking both Anavar and warfarin constitutes a medical emergency.

Can You Take Anavar if You Are on Warfarin or Another Blood Thinner?

The FDA’s position is that Anavar and warfarin can be co-administered, but only under close medical supervision with frequent INR monitoring and significant warfarin dose reduction. The prescribing information recommends that when oxandrolone therapy is initiated in a patient already receiving warfarin, the INR should be monitored closely and the warfarin dose adjusted until a stable target INR has been achieved. The same monitoring is recommended when the oxandrolone dose is changed or discontinued, because the interaction effect will diminish as oxandrolone clears.

In practice, this means that if you are on warfarin and want to run Anavar, you must involve your prescribing physician. The warfarin dose will likely need to be reduced by 70 to 85% during the Anavar cycle, with INR testing every 2 to 3 days initially until a stable level is achieved. When you stop Anavar, the warfarin dose will need to be gradually increased back to its pre-Anavar level, again with frequent INR monitoring during the transition. This is not something that can be self-managed.

The more conservative and safer approach is to avoid the combination entirely. If you require ongoing anticoagulation and want to use anabolic steroids, discuss the situation with your haematologist or cardiologist. They may advise switching to a direct oral anticoagulant (DOAC) for the duration of the cycle, or they may determine that the combination is too risky given your specific clinical situation.

Does the Anavar and Warfarin Interaction Apply to Other Anticoagulants Like Rivaroxaban or Apixaban?

The specific clinical study data exists only for the warfarin-oxandrolone combination. The DOACs (rivaroxaban, apixaban, edoxaban, dabigatran) have different mechanisms: they directly inhibit specific clotting factors (Factor Xa for rivaroxaban, apixaban, and edoxaban; thrombin for dabigatran) rather than inhibiting vitamin K-dependent clotting factor synthesis like warfarin does.

The pharmacodynamic component of the interaction (increased sensitivity of clotting factor synthesis) is specific to warfarin and other vitamin K antagonists. It does not apply to DOACs. However, the pharmacokinetic component (hepatic CYP450 competition) could theoretically affect any medication metabolised by the same enzyme pathways. Rivaroxaban is metabolised partly by CYP3A4 and CYP2J2; apixaban by CYP3A4. If oxandrolone competes for these enzymes, the DOAC’s metabolism could be slowed, increasing its plasma concentration and bleeding risk.

No clinical study has investigated the oxandrolone-DOAC interaction. The theoretical risk is lower than with warfarin (because the pharmacodynamic enhancement does not apply), but it is not zero. If you are on any anticoagulant and considering Anavar, discuss the interaction risk with your prescribing physician. Do not assume that because the FDA warning specifically names warfarin, other anticoagulants are automatically safe.

Does This Interaction Apply to Other Anabolic Steroids or Just Anavar?

The class effect extends to all androgenic anabolic steroids. The prescribing information states that anabolic androgenic steroids as a class may increase susceptibility to oral anticoagulants. Case reports of increased INR and bleeding have been published for oxymetholone, methyltestosterone, danazol, and testosterone in patients on warfarin. Oxandrolone is the only compound for which a dedicated pharmacokinetic interaction study was conducted, which is why the magnitude of the effect (80-85% dose reduction) is precisely quantified for this compound specifically.

If you are on warfarin and considering any AAS, including injectable testosterone enanthate or testosterone cypionate, the same principle of close INR monitoring and warfarin dose adjustment applies. The magnitude of the interaction may differ by compound (oral steroids with hepatic first-pass are likely to produce a larger pharmacokinetic interaction than injectables), but the direction of the effect (increased anticoagulation, increased bleeding risk) is consistent across the class.

Frequently Asked Questions

How dangerous is the Anavar and warfarin interaction?

Potentially life-threatening. The FDA clinical study required an 80 to 85% reduction in warfarin dose to prevent supratherapeutic anticoagulation. Microscopic haematuria occurred in 60% of subjects even under controlled conditions. An unmonitored patient who starts Anavar on a stable warfarin dose risks INR elevation to levels associated with major haemorrhage, including intracranial bleeding. This is one of the most clinically significant drug interactions in AAS pharmacology.

Can I just increase my INR monitoring instead of reducing my warfarin dose?

No. Monitoring alone does not prevent the interaction. The warfarin dose must be reduced proactively when Anavar is started. Waiting for the INR to rise before adjusting means the patient has already been exposed to supratherapeutic anticoagulation. The FDA recommendation is to initiate close monitoring and dose adjustment simultaneously when oxandrolone therapy begins. Monitoring without dose reduction is not an acceptable management strategy.

Is aspirin or clopidogrel also affected by this interaction?

Aspirin and clopidogrel are antiplatelet agents, not anticoagulants. They work through different mechanisms (cyclooxygenase inhibition and P2Y12 receptor blockade, respectively) and are not subject to the same CYP450 and vitamin K-dependent interaction that drives the Anavar and warfarin potentiation. However, any antiplatelet agent increases baseline bleeding risk, and combining antiplatelet therapy with AAS-induced haematocrit elevation (which increases blood viscosity and shear stress on vessels) is a separate concern worth discussing with your physician.

If I stop Anavar, does the warfarin interaction resolve immediately?

No. Oxandrolone clears within 48 to 72 hours (given the 9-hour half-life), but the hepatic enzyme induction or inhibition effects and the pharmacodynamic sensitisation take longer to normalise. The warfarin dose should be gradually increased back to the pre-Anavar level over 1 to 2 weeks after stopping Anavar, with INR testing every 3 to 4 days during the transition. Abruptly returning to the full pre-Anavar warfarin dose risks supratherapeutic anticoagulation because the interaction effect fades gradually, not instantly.

Should this interaction stop me from using Anavar entirely?

If you are on warfarin for a life-threatening condition (mechanical heart valve, recurrent pulmonary embolism, high-risk atrial fibrillation), the risk of disrupting your anticoagulation to accommodate an AAS cycle is almost never justified. If you are on warfarin for a lower-risk indication and have a flexible relationship with your prescribing physician, the interaction can be managed with close monitoring, but the complexity and risk are substantial. For most users on anticoagulant therapy, the safer decision is to avoid oral AAS entirely and discuss alternative approaches with their physician.